The table below shows Stoke Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$60.58M
$131.83M
-$24.57M
-$21.36M
$32.49M
-$20.14M
Capital expenditure
$353.00K
$152.00K
$12.00K
$165.00K
$841.00K
$204.00K
Investing cash flow
$50.69M
$13.63M
$9.99M
$53.09M
-$135.78M
-$204.00K
Dividends paid
-
-
-
-
STOK operating cash flow (10-K history)
Stoke Therapeutics, Inc. reported operating cash flow of $45.59M for fiscal year 2025. That is up 152.5% from -$86.85M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$10.96M (FY 2018) to $45.59M. Figures come from the company's audited annual reports as filed with the SEC.